Immunotherapy combo shows promise in head and neck cancer trial
NCT ID NCT03480672
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy and radiation after surgery could help prevent cancer from returning in people with advanced head and neck cancer. The study enrolled 211 patients who had their tumors completely removed. The goal was to see if the combination improved the time patients lived without their cancer coming back. Results are not yet final, but the study aims to find a more effective treatment for this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) plus cisplatin chemotherapy
What this could lead to
If successful, this could lead to a new standard treatment that lowers the chance of cancer returning after surgery for high-risk head and neck cancer.
What could go wrong
This is a phase 2 trial with only 211 participants, so results are preliminary. Adding pembrolizumab may increase side effects without improving survival, and the benefit may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitätsmedizin Berlin; Klinik für Radioonkologie und Strahlentherapie CVK
Berlin, Germany
-
Charité - Universitätsmedizin, CVK und CCM, Klinik für Hals-Nasen-Ohrenheilkunde
Berlin, Germany
-
Department of Head Medicine and Oral Health, University of Leipzig
Leipzig, 04103, Germany
-
Ernst von Bergmann Klinikum Potsdam, Zentrum für Hämatologie, Onkologie und Strahlenheilkunde, Klinik für Hämatologie und
Potsdam, Germany
-
Helios Klinikum Erfurt GmbH, Klinik für Hals-Nasen-Ohrenheilkunde
Erfurt, Germany
-
Kath. Marienkrankenhaus gGmbH, Zentrum für Innere Medizin Hämatologie/Onkologie
Hamburg, Germany
-
Klinikum Bielefeld, Onkologie/Hämatologie/ Palliativmedizin
Bielefeld, Germany
-
Klinikum Stuttgart - Katharinenhospital, Klinik für Radioonkologie und Strahlentherapie
Stuttgart, Germany
-
UNIVERSITÄTSKLINIKUM Schleswig-Holstein, Campus Lübeck
Lübeck, Germany
-
Universitätsklinikum Bonn; Med. Klinik III / ZIM, Hämatologie/Onkologie
Bonn, Germany
-
Universitätsklinikum Düsseldorf, Klinik für Strahlentherapie und Radiologische Onkologie
Düsseldorf, Germany
-
Universitätsklinikum Essen, Klinik und Poliklinik für Strahlentherapie
Essen, Germany
-
Universitätsklinikum Jena, Klinik für Hals-Nasen-Ohrenheilkunde
Jena, Germany
-
Universitätsklinikum Mannheim, Hals-Nasen-Ohren Klinik
Mannheim, Germany
-
Universitätsklinikum Regensburg, Klinik und Poliklinik für Strahlentherapie
Regensburg, Germany
-
Universitätsklinikum Würzburg; Klinik und Poliklinik für Strahlentherapie
Würzburg, Germany